NO2120568T3 - - Google Patents

Info

Publication number
NO2120568T3
NO2120568T3 NO08730048A NO08730048A NO2120568T3 NO 2120568 T3 NO2120568 T3 NO 2120568T3 NO 08730048 A NO08730048 A NO 08730048A NO 08730048 A NO08730048 A NO 08730048A NO 2120568 T3 NO2120568 T3 NO 2120568T3
Authority
NO
Norway
Application number
NO08730048A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690832&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2120568(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2120568T3 publication Critical patent/NO2120568T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00Chemistry: analytical and immunological testing
    • Y10T436/14Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
NO08730048A 2007-02-16 2008-02-15 NO2120568T3 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90177207P 2007-02-16 2007-02-16
US96519607P 2007-08-17 2007-08-17
PCT/US2008/054168 WO2008101214A2 (en) 2007-02-16 2008-02-15 Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders

Publications (1)

Publication Number Publication Date
NO2120568T3 true NO2120568T3 (no) 2018-04-14

Family

ID=39690832

Family Applications (1)

Application Number Title Priority Date Filing Date
NO08730048A NO2120568T3 (no) 2007-02-16 2008-02-15

Country Status (20)

Country Link
US (2) US8092828B2 (no)
EP (3) EP3300601B1 (no)
JP (1) JP5314600B2 (no)
KR (2) KR20150038752A (no)
CN (1) CN105998046A (no)
AU (1) AU2008216083B2 (no)
CA (1) CA2678332C (no)
CY (1) CY1119631T1 (no)
DK (2) DK2120568T3 (no)
ES (2) ES2909903T3 (no)
FR (1) FR22C1034I2 (no)
HK (1) HK1253378A1 (no)
HR (1) HRP20220428T3 (no)
HU (2) HUE058334T2 (no)
NL (1) NL301185I2 (no)
NO (1) NO2120568T3 (no)
PL (2) PL2120568T3 (no)
PT (2) PT3300601T (no)
SI (1) SI3300601T1 (no)
WO (1) WO2008101214A2 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100075937A1 (en) * 2008-09-24 2010-03-25 Hollis-Eden Pharmaceuticals, Inc. Patient populations and treatment methods
KR102284689B1 (ko) * 2011-10-21 2021-08-02 셀라토 파마슈티칼즈, 인코포레이티드 동결건조된 리포좀
US20140154304A1 (en) * 2012-11-30 2014-06-05 Boehringer Ingelheim International Gmbh Combination therapy with volasertib
WO2015127173A1 (en) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015127172A1 (en) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3373919A4 (en) 2015-11-11 2019-06-19 Celator Pharmaceuticals, Inc. TESTS AND METHODS FOR SELECTION OF A TREATMENT PLAN FOR A PERSON WITH LEUKEMIA
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2019023873A1 (zh) * 2017-07-31 2019-02-07 江苏竞诺择生物医药科技有限公司 一种用于治疗造血***增殖性疾病的纳米脂质微粒组合物及药用组合物
MX2021003527A (es) * 2018-09-25 2021-05-27 Celator Pharmaceuticals Inc Tratamiento de baja intensidad de trastornos hematologicos.
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
ZA200503653B (en) * 2002-11-06 2006-08-30 Celgene Corp Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
BR0215935A (pt) * 2002-11-06 2005-08-09 Wyeth Corp Terapia combinada para tratamento de leucemia aguda e sìndrome mielodisplásica
PT1744764E (pt) 2004-04-22 2012-08-30 Celator Pharmaceuticals Inc Formulações lipossómicas de agentes antraciclina e análogos de citidina
SE0402025D0 (sv) * 2004-08-13 2004-08-13 Active Biotech Ab Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
WO2007076117A2 (en) 2005-12-22 2007-07-05 Celator Pharmaceuticals, Inc. Liposomal formulations comprising secondary and tertiary amines and methods for preparing thereof

Also Published As

Publication number Publication date
EP2120568A2 (en) 2009-11-25
EP3300601A1 (en) 2018-04-04
AU2008216083A1 (en) 2008-08-21
CA2678332A1 (en) 2008-08-21
PT3300601T (pt) 2022-04-21
EP2120568A4 (en) 2010-04-21
JP2010519224A (ja) 2010-06-03
US8092828B2 (en) 2012-01-10
HUE058334T2 (hu) 2022-07-28
HK1253378A1 (zh) 2019-06-14
FR22C1034I2 (fr) 2023-06-30
AU2008216083B2 (en) 2014-02-06
CY1119631T1 (el) 2018-04-04
AU2008216083A2 (en) 2009-09-24
ES2650167T3 (es) 2018-01-17
HRP20220428T3 (hr) 2022-05-27
HUS2200032I1 (hu) 2022-07-28
WO2008101214A3 (en) 2008-11-20
FR22C1034I1 (fr) 2022-09-09
PL3300601T3 (pl) 2022-05-02
KR20100014441A (ko) 2010-02-10
JP5314600B2 (ja) 2013-10-16
DK3300601T3 (da) 2022-03-21
ES2909903T3 (es) 2022-05-10
CA2678332C (en) 2015-06-02
US20080199515A1 (en) 2008-08-21
EP2120568B1 (en) 2017-11-15
EP4046640A1 (en) 2022-08-24
DK2120568T3 (en) 2017-12-11
EP3300601B1 (en) 2022-01-12
US20100303895A1 (en) 2010-12-02
PL2120568T3 (pl) 2018-03-30
CN105998046A (zh) 2016-10-12
SI3300601T1 (sl) 2022-05-31
KR20150038752A (ko) 2015-04-08
NL301185I2 (nl) 2022-07-21
WO2008101214A2 (en) 2008-08-21
PT2120568T (pt) 2017-12-04

Similar Documents

Publication Publication Date Title
NO2120568T3 (no)
CN300846893S (zh) 夜灯(5)
CN300728927S (zh) 桌子(9)
CN300729091S (zh) 杯(华夏神龙)
CN300729082S (zh) 盘子
CN300729024S (zh) 桌布
CN300727814S (zh) 电倍司
CN300765974S (zh) 礼盒(月满楼)
CN300728874S (zh) 椅子(32)
CN300771945S (zh) 下移塑组件
CN300727735S (zh) 洗衣机波轮
CN300760840S (zh) 秋千椅(方管扶手特斯林)
CN301457769S (zh) 记号笔
CN300728737S (zh) 糖果包装纸(三)
CN300909614S (zh) 道闸(bs106)
CN300728495S (zh) 宠物玩具(咬骨一)
CN300728433S (zh) 支架灯(ch1118)
CN300728423S (zh) 台灯(8)
CN300882330S (zh) 柜子(书台组合r1-st402g)
CN300774129S (zh) 编织帘片材(bs-p05)
CN300790855S (zh) 针织纬编机(出口型系列)
CN300793784S (zh) 台灯(11)
CN300802535S (zh) 床(a103)
CN300731574S (zh) 书柜(hd3002)
CN300728297S (zh) 型材(ymgr5316)